Literature DB >> 10654072

Effect of cholecystokinin-2 receptor blockade on rat stomach ECL cells. A histochemical, electron-microscopic and chemical study.

D Chen1, C M Zhao, P Norlén, M Björkqvist, X Q Ding, M Kitano, R Håkanson.   

Abstract

The ECL cells in the oxyntic mucosa of rat stomach produce histamine and chromogranin A-derived peptides such as pancreastatin. The cells respond to gastrin via cholecystokinin-2 (CCK2) receptors. A CCK2 receptor blockade was induced by treatment (for up to 8 weeks) with two receptor antagonists, YM022 and YF476. Changes in ECL-cell morphology were examined by immunocytochemistry and electron microscopy, while changes in ECL cell-related biochemical parameters were monitored by measuring serum pancreastatin and oxyntic mucosal pancreastatin, and histamine concentrations, and histidine decarboxylase (HDC) activity. The CCK2 receptor blockade reduced the ECL-cell density only marginally, if at all, but transformed the ECL cells from slender, elongated cells with prominent projections to small, spherical cells without projections. The Golgi complex and the rough endoplasmic reticulum were diminished. Secretory vesicles were greatly reduced in volume density in the trans Golgi area. Circulating pancreastatin concentration and oxyntic mucosal HDC activity were lowered within a few hours. Oxyntic mucosal histamine and pancreastatin concentrations were reduced only gradually. The CCK2 receptor blockade was found to prevent the effects of omeprazole-evoked hypergastrinaemia on the ECL-cell activity and density. In conclusion, gastrin, acting on CCK2 receptors, is needed to maintain the shape, size and activity of the ECL cells, but not for maintaining the ECL-cell population.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10654072     DOI: 10.1007/s004419900136

Source DB:  PubMed          Journal:  Cell Tissue Res        ISSN: 0302-766X            Impact factor:   5.249


  11 in total

Review 1.  Secretory organelles in ECL cells: effects of pharmacological blockade of the gastrin/CCK2 receptor versus its elimination by gene targeting.

Authors:  Chun-Mei Zhao; Rolf Håkanson; Duan Chen
Journal:  Inflammopharmacology       Date:  2005       Impact factor: 4.473

2.  Mobilization of rat stomach ECL-cell histamine in response to short- or long-term treatment with omeprazole and/or YF 476 studied by gastric submucosal microdialysis in conscious rats.

Authors:  T Konagaya; M Bernsand; P Norlén; R Håkanson
Journal:  Br J Pharmacol       Date:  2001-05       Impact factor: 8.739

3.  Long-lasting cholecystokinin(2) receptor blockade after a single subcutaneous injection of YF476 or YM022.

Authors:  M Kitano; P Norlén; X Q Ding; S Nakamura; R Håkanson
Journal:  Br J Pharmacol       Date:  2000-06       Impact factor: 8.739

4.  Effect of repeated doses of netazepide, a gastrin receptor antagonist, omeprazole and placebo on 24 h gastric acidity and gastrin in healthy subjects.

Authors:  Malcolm Boyce; Steve Warrington
Journal:  Br J Clin Pharmacol       Date:  2013-11       Impact factor: 4.335

5.  Netazepide, a gastrin/cholecystokinin-2 receptor antagonist, can eradicate gastric neuroendocrine tumours in patients with autoimmune chronic atrophic gastritis.

Authors:  Malcolm Boyce; Andrew R Moore; Liv Sagatun; Bryony N Parsons; Andrea Varro; Fiona Campbell; Reidar Fossmark; Helge L Waldum; D Mark Pritchard
Journal:  Br J Clin Pharmacol       Date:  2016-11-21       Impact factor: 4.335

6.  Effect of netazepide, a gastrin/CCK2 receptor antagonist, on gastric acid secretion and rabeprazole-induced hypergastrinaemia in healthy subjects.

Authors:  Malcolm Boyce; Sally Dowen; Gillian Turnbull; Frans van den Berg; Chun-Mei Zhao; Duan Chen; James Black
Journal:  Br J Clin Pharmacol       Date:  2015-05       Impact factor: 4.335

7.  Deletion of Men1 and somatostatin induces hypergastrinemia and gastric carcinoids.

Authors:  Sinju Sundaresan; Anthony J Kang; Michael M Hayes; Eun-Young K Choi; Juanita L Merchant
Journal:  Gut       Date:  2016-02-09       Impact factor: 23.059

8.  Control of gastric acid secretion in somatostatin receptor 2 deficient mice: shift from endocrine/paracrine to neurocrine pathways.

Authors:  Chun-Mei Zhao; Vicente Martinez; Laura Piqueras; Lixin Wang; Yvette Taché; Duan Chen
Journal:  Endocrinology       Date:  2007-11-01       Impact factor: 4.736

Review 9.  Role of CCK/gastrin receptors in gastrointestinal/metabolic diseases and results of human studies using gastrin/CCK receptor agonists/antagonists in these diseases.

Authors:  Marc J Berna; Robert T Jensen
Journal:  Curr Top Med Chem       Date:  2007       Impact factor: 3.295

10.  The type 2 CCK/gastrin receptor antagonist YF476 acutely prevents NSAID-induced gastric ulceration while increasing iNOS expression.

Authors:  Dominic-Luc Webb; Tobias Rudholm-Feldreich; Linda Gillberg; Md Abdul Halim; Elvar Theodorsson; Gareth J Sanger; Colin A Campbell; Malcolm Boyce; Erik Näslund; Per M Hellström
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-11-24       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.